CLDX Stock Overview
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Celldex Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$35.68|
|52 Week High||US$57.20|
|52 Week Low||US$15.37|
|1 Month Change||-25.47%|
|3 Month Change||-34.21%|
|1 Year Change||81.95%|
|3 Year Change||819.11%|
|5 Year Change||-36.57%|
|Change since IPO||-68.83%|
Recent News & Updates
Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
21st Century advances on 20th century genetic technologies have opened Celldex Therapeutics Inc.’s developments aimed specifically at induced weaknesses. At this point of the market they also outdo the prospects of many stocks widely-held by Seeking Alpha readers, contributors, and commenters. This is an article about stock prices more than about healthcare technologies, which have been extensively considered by those with appropriate expertise. For investment in portfolios where wealth-building is a principal objective, evolving economics now make biotech industry stocks leading candidates.
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Celldex...
|CLDX||US Biotechs||US Market|
Return vs Industry: CLDX exceeded the US Biotechs industry which returned 1.8% over the past year.
Return vs Market: CLDX exceeded the US Market which returned 19.4% over the past year.
|CLDX Average Weekly Movement||6.3%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||6.1%|
|10% most volatile stocks in US Market||14.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: CLDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CLDX's weekly volatility (6%) has been stable over the past year.
About the Company
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company’s clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company’s proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
Celldex Therapeutics Fundamentals Summary
|CLDX fundamental statistics|
Is CLDX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CLDX income statement (TTM)|
|Cost of Revenue||US$49.06m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.55|
|Net Profit Margin||-891.92%|
How did CLDX perform over the long term?See historical performance and comparison
Is Celldex Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CLDX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CLDX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CLDX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CLDX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CLDX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CLDX is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (2.8x).
How is Celldex Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLDX's revenue is expected to decline over the next 3 years (-26.5% per year).
High Growth Revenue: CLDX's revenue is forecast to decline over the next 3 years (-26.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLDX's Return on Equity is forecast to be high in 3 years time
How has Celldex Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLDX is currently unprofitable.
Growing Profit Margin: CLDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CLDX is unprofitable, but has reduced losses over the past 5 years at a rate of 21.9% per year.
Accelerating Growth: Unable to compare CLDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: CLDX has a negative Return on Equity (-16.55%), as it is currently unprofitable.
How is Celldex Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CLDX's short term assets ($426.6M) exceed its short term liabilities ($14.2M).
Long Term Liabilities: CLDX's short term assets ($426.6M) exceed its long term liabilities ($9.3M).
Debt to Equity History and Analysis
Debt Level: CLDX is debt free.
Reducing Debt: CLDX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLDX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CLDX has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 18.1% each year
What is Celldex Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CLDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CLDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CLDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CLDX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CLDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Anthony Marucci (59 yo)
Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...
CEO Compensation Analysis
Compensation vs Market: Anthony's total compensation ($USD3.01M) is about average for companies of similar size in the US market ($USD3.72M).
Compensation vs Earnings: Anthony's compensation has increased whilst the company is unprofitable.
Experienced Management: CLDX's management team is considered experienced (4.5 years average tenure).
Experienced Board: CLDX's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.
Celldex Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Celldex Therapeutics, Inc.
- Ticker: CLDX
- Exchange: NasdaqCM
- Founded: 1983
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.665b
- Shares outstanding: 46.66m
- Website: https://www.celldex.com
Number of Employees
- Celldex Therapeutics, Inc.
- Perryville III Building
- Suite 220
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/04 00:06|
|End of Day Share Price||2021/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.